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ABSTRACT
Purpose: Focused ultrasound (FUS) is a modality with rapidly expanding applications across
Medicine. Treatment of bone lesions with FUS including both benign and malignant tumors has
been an active area of investigation. Recently, as a result of a successful phase III trial, magnetic
resonance guided FUS is now a standardized option for treatment of painful bone metastases.
This report reviews the clinical applications amenable to treatment with FUS and provides
background on FUS and image guidance techniques, results of clinical studies, and future
directions.
Methods: A comprehensive literature search and review of abstracts presented at the recently
completed 4th International Focused Ultrasound Symposium was performed. Case reports and
older publications revisited in more recent studies were excluded. For clinical studies that extend
beyond bone tumors, only the data regarding bone tumors are presented.
Results: Fifteen studies assessing the use of focused ultrasound in treatment of primary benign
bone tumors, primary malignant tumors, and metastastic tumors meeting the search criteria were
identified. For these clinical studies the responders group varied within 91-100%, 85-87% and
64-94%, respectively. Major complications were reported in the ranges 0%, 0-28% and 0-4% for
primary benign, malignant and metastatic tumors, respectively.
Conclusions: Image-guided FUS is both safe and effective in the treatment of primary and
secondary tumors. Additional phase III trials are warranted to more fully define the role of FUS
in treatment of both benign and malignant bone tumors.
Keywords: High-Intensity Focused Ultrasound, Ablation, Bone tumor, Pain palliation, Image
guidance.
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1. INTRODUCTION
Bone tumors, whether benign or malignant, often present challenges with local disease control
and pain. Several bone tumor clinical studies have been conducted in the last decade, focused on
both curative and palliative treatments. One emerging modality in treatment of bone tumors is
high intensity focused ultrasound (FUS), which causes thermal damage of tissue using focused
sound waves. The FUS treatment is guided in real-time by magnetic resonance (MRgFUS) or
ultrasonography (USgFUS), which provides a feedback mechanism to increase treatment
accuracy. This technique is non-invasive and does not use ionizing radiation, which contrasts
with standard approaches, such as surgery or radiotherapy, used in cancer treatment. The aim of
this paper is to review bone tumor clinical studies using both USgFUS and MRgFUS, including
benign tumors, primary malignancies, and metastatic bone tumors.
The vast majority of primary bone tumors are benign. Many are asymptomatic and thus remain
undetected until radiographic examinations are performed for other reasons. Thus, the actual
incidence of benign bone tumors is currently indeterminate [1]. One of the most common is
osteoid osteoma, comprising nearly 10% of benign bone tumors [2]. It consists of a nidus, or
core of growing cells, surrounded by a thick bony shell that is normally found in the
appendicular skeleton [3]. They are predominantly seen in children, teenagers, and young adults,
with more than 80% of tumors seen in individuals between the ages of 5 and 30 years [4]. The
presence of a benign bone lesion does not necessarily mean lack of aggressiveness; histologically
benign lesions may be locally highly aggressive, causing severe discomfort and pain [5].
Malignant primary bone tumors constitute 0.2% of all malignancies in adults and approximately
5% of childhood malignancies [1]. The most common primary malignant bone tumor is
osteosarcoma, representing 35% of total primary bone malignancies [6]. The 5-year overall
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survival rate for bone sarcoma is 68%. Osteosarcomas usually develop in areas where the bone is
growing quickly, such as near the ends of the long bones, and are most common in children and
young adults. These particular tumors require aggressive local treatment and at times may
require amputation.
Bone metastases are the most common source of pain in cancer patients [7]. Autopsy studies
have shown that up to 85% of patients with breast, prostate and lung cancer have bone
metastases at the time of death. Complications due to skeletal metastases, including intractable
pain, fracture, and decreased mobility, can dramatically reduce performance and quality of life
and lead to depression and anxiety [8]. Bone metastases portend a poor prognosis, with patients
generally facing a median survival of 3 years or less. In lung cancer, survival is typically
measured in months, whereas patients with breast cancer or prostate cancer often live for several
years. Bone metastases are generally classified as osteolytic which is characterized by
destruction of normal bone or osteoblastic characterized by deposition of new bone. This
distinction is not absolute since metastatic lesions can contain both osteolytic and osteoblastic
components [9].
There are two distinct treatment approaches for bone tumors: curative and palliative. For thermal
ablation techniques, in particular, curative treatment aims for complete coagulation necrosis of
the primary lesion. In palliative treatment of primary or secondary bone tumors, therapeutic
goals include pain palliation, tumor reduction, prevention of impending pathologic fractures,
and/or tumor decompression. The denervation of the periosteum, which contains pain-reporting
nerve fibers, is considered a major factor in pain palliation. This explains the rapid relief
following ultrasound treatment which is characterized by enhanced power deposition in bone
relative to surrounding soft tissues [10].
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Clinical applications of thermal ablation therapy are expanding rapidly due to the ability to
produce immediate obliteration of either small tumors or benign disease, when the target volume
is located in an anatomic region with sufficient biological reserve and/or separation from
surrounding critical normal tissues. Either cryogenic temperatures (<-40C) or high temperatures
>50-60C produce complete ablation of the tissue vasculature and most importantly disrupt and
coagulate all structural proteins in the target cells. These effects are non-subtle and irreversible,
leading to immediate and complete cellular death. In lower dose regions, in the transition zone of
a thermally coagulated lesion, there is a percentage of cells that survive the thermal insult. In this
border region, adjunctive therapies such as radiation or chemotherapy may be helpful in further
expanding the radial penetration of effective therapy, by providing some differential effect on
weaker tumor cells relative to the surrounding normal tissue host.
There are numerous technologies available to produce a high intensity heat focus at depth in
tissue. Invasive approaches include interstitial or intracavitary placement of radiofrequency
(RFA), microwave (MWA), laser, or thermal conduction sources into the target region (Table I).
These implantable heat sources are well-characterized in the literature [11-14], and for many
tissue sites like liver, breast, prostate, kidney and lung, they can heat deep tissue targets
effectively without unacceptable normal tissue complications [4, 15]. Insertion of heat sources
directly into bone tissue is difficult however, such that a non-invasive approach with precise
control of the focal zone at depth is required. Taking advantage of the short wavelength and deep
penetration of ultrasound pressure waves, beams may be combined from large external
transducer arrays to produce an intense focal hot spot at depth non-invasively; thus the name
high intensity focused ultrasound (FUS).
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2. METHODS
This section reviews the FUS method, image guidance techniques, and FUS devices used in
ongoing clinical studies. Furthermore, we address primary and secondary endpoints typical in the
analyzed clinical studies as well as the tools for outcome assessment.

2.1. High-Intensity Focused Ultrasound
In general, ultrasound systems produce an acoustic pressure wave from one or more piezoelectric
transducers that operate at a frequency in the range of 0.2-4 MHz. Attenuation of ultrasound
energy as it propagates through biologic tissue results in a rise of temperature in the treated
volume. Coagulative necrosis and cell death occur within seconds at temperatures in the range of
65-85°C [16], so that the ablative treatment must be well localized to the tumor target and avoid
surrounding normal tissues. To achieve the required focusing and rapid elevation of tissue
temperature at depth, the ultrasound energy is usually intensified at a focal spot by using multiple
intersecting ultrasound beams that converge on the target. Typical clinical focused ultrasound
systems produce high intensity focal volumes of 0.2-20 mm3 at depth, while spreading out the
ultrasound energy over a large surface area under the transducer array so as to have negligible
effect on tissues outside the focus. Because of the high temperatures achieved in the high
intensity focus, sonications are generally limited in duration to only a few seconds. This reduces
the potentially detrimental thermal smearing and energy dissipation effects to surrounding tissue
due to blood perfusion. Because of these technical issues, ablation of a typical tumor requires
sequential tiling of multiple sonications to create homogeneous thermal damage and coagulative
necrosis of the entire target volume [16, 17].
With focused ultrasound systems, tissue in the path of the ultrasound beams outside the focus is
warmed, but only to sub-lethal temperatures. Between successive sonications, the heat deposited
6

in intervening tissue is dissipated by normal tissue conduction and perfusion cooling effects [18].
Due to the low thermal conductivity and high ultrasound attenuation in the periosteum and bone
cortex, it is possible to use lower energy levels when treating bone compared to treatment of
well-perfused soft tissue. This provides an improved safety profile by reducing thermal damage
around the treated bone site [19-21].
2.1.1. Image-guided FUS
Over the past decades, there have been numerous external ultrasound array systems for focused
heating in the body, [22-27] including one system specifically optimized for small animal
treatments [28]. At present, there are three commercial non-invasive ultrasound heating systems
that have been integrated within either US or MR imaging systems for image-guidance of FUS
treatments in humans: the ExAblate system (InSightec Ltd., Tirat Carmel, Israel) based on the
General Electric MR platform [29, 30]; the Sonalleve FUS system (Koninklijke Philips
Electronics NV, Eindhoven, The Netherlands) based on the Phillips MR platform [31, 32]; and
the Haifu system (Model JC, Chongqing Haifu Medical Technology Co. Ltd., Chongqing,
China) coupled with a B-type ultrasonography system [33].
In USgFUS, the US imaging probe is situated in the center of therapeutic transducer array and
provides real-time sonography feedback. This way, the user can target the lesion to be treated,
guide the US energy deposition, and assess the extent of acute coagulation necrosis in the treated
tissue [19, 33, 34]. MRI adds to focused ultrasound therapy the advantages of high resolution
lesion localization, real time temperature monitoring, and post-treatment tissue evaluation.
Lesion visualization is achieved through the intrinsic high tissue contrast of MRI, while
temperature monitoring is achieved through use of specific MRI sequences (proton resonance
frequency shift method - PRF) performed during the ablation [17].
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2.2. Clinical studies
This review summarizes clinical studies to date assessing use of therapeutic ultrasound for bone
tumors, including both benign and malignant primary lesions, as well as metastatic disease. Case
reports were excluded from analysis. In instances of published updates of previous studies, only
the more complete publications were analyzed. For clinical studies that extend beyond bone
tumors, only the data regarding bone tumors are presented [34, 35]. The 4th Focused Ultrasound
Symposium (October 12-16, 2014 in North Bethesda, Maryland USA) reported significant
advances in the FUS treatment of bone tumors, and abstracts from that recent meeting were
considered under the aforementioned inclusion criteria. The following sections summarize the
most relevant aspects of clinical trial design: inclusion criteria for patient selection, endpoints,
and instruments for outcome assessment.
2.2.1. Inclusion criteria for patient selection
For safe and effective ablation therapy, carefully defined patient selection criteria are critically
important. The anatomy of the human skeleton necessarily involves many critical neighboring
structures. Patients with bone tumors in difficult to access locations or in close proximity to
major nerves, e.g. spinal tumors, have been typically excluded from clinical studies. Some
studies also excluded patients with tumors that are: larger than 10 cm [19], close to the joints
[36], close to blood vessels [33], in weight-bearing bones [18, 20], or with locally advanced
disease [35].
Patients with bone metastases were included in published studies only if they reported moderate
or severe pain, typically a score of 4 or greater out of 10 for worst pain in a 24-hour period.
Furthermore, patients with more than 1-2 metastatic sites were excluded since this type of pain is
believed to be better treated with a systemic rather than focal approach [4]. In the case of
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MRgFUS, MR compatibility must be considered and patients with claustrophobia or pacemakers
were excluded from this image guidance technique. Some studies aimed for primary treatment,
so patients with previous radiotherapy were excluded [37].
The Karnofsky Performance Status Scale is widely used to quantify the functional status of
cancer patients [38]. One study in particular did not consider patients with a Karnofsky score
lower than 70% [19]. Finally, some patients were enrolled only if there was no other treatment
technique available or feasible [18-21, 33, 35].
2.2.2. Endpoints and instruments for outcome assessment
The primary endpoints of a clinical study are typically safety (Phase I) and efficacy (Phases II
and III). Safety is assessed by occurrence of adverse events, which can be divided into minor and
major complications [39]. The definition of efficacy is dependent on the type of tumor and intent
of treatment. For primary bone tumors, either malignant or benign, efficacy is analyzed in terms
of local tumor control, survival, recurrence, and/or conservation of the diseased-limb. On the
other hand, treatments for bone metastases aim for pain palliation and improved quality of life;
where quality of life is considered a secondary endpoint. Geiger et al. also distinguish technical
and clinical endpoints [17]. The technical endpoints address short-term complications from the
FUS procedure, and will be considered under the umbrella of safety. In palliative treatments,
pain progression is also considered.
Different instruments were used to quantify each target outcome, including questionnaires for
pain and quality of life assessment, as well as anatomical imaging (CT, MRI, or CE-MRI),
functional imaging (PET/CT, SPECT, or scintigraphy), biochemical (e.g. alkaline phosphatase)
and histopathology analyses for determination of response. Each clinical study used one or more
of these instruments to evaluate clinical outcome.
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Safety
The safety endpoint is evaluated in terms of incidence and severity of complications due to the
FUS treatment. These adverse events must be assessed by clinical and imaging examinations,
where the latter are especially relevant to detect occult adverse events. Some authors (e.g. [19])
subdivide this endpoint into minor and major complications, where the latter are events that lead
to substantial morbidity, disability, increased level of care, or results in hospital admission or
substantially lengthened hospital stay [40]. We standardized this classification for all studies.
Local tumor control
Local tumor control is generally accessed via imaging (SPECT, MRI or PET/CT), and may also
be assessed with biochemistry and histopathology analysis. Several parameters can be analyzed:
inflammatory status; bone remodeling and/or remineralization; tumor vascularity and perfusion;
tumor cellular survival and activity; coagulative necrosis of the target area, and particularly
tumor size. For primary malignant bone tumors, the presence and condition of metastatic lesions
are also evaluated, e.g., using chest radiography and/or CT to define lung metastases [19].
Furthermore, biochemical markers for cancer are also assessed in all clinical studies that address
primary malignancies [19, 33, 34]. To evaluate treatment efficacy via local tumor control, lesion
changes were evaluated by Napoli et al. [37] in accordance with the MD Anderson (MDA)
criteria [41]. These criteria include quantitative and qualitative assessments of the behavior of
bone metastases. The response is divided into four categories: complete response (CR), partial
response (PR), progressive disease (PD), and stable disease (SD). Quantitatively, these criteria
define PR as a decrease of 50% or more in the sum of the perpendicular measurements of a
lesion and PD as an increase of 25% or more in this sum.
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Pain palliation
Patient response to treatment was measured by using the Brief Pain Inventory (BPI), a validated
numeric scale for the evaluation of pain in cancer patients [42]. In this evaluation, patients were
asked to rate their worst pain with allowed responses ranging typically from a score of 0 to 10 (0
= no pain, 10 = pain as bad as you can imagine). Two different names were used for this 11-point
scale: numerical rating scale (NRS) and visual analog scale (VAS). Geiger et al. [17] also used
the terminology VAS, but for a 1-10 range. Finally, Li et al. [33] used a 4-point pain scale (0-3)
named verbal rating scale (VRS).
Another assessment of palliative therapy is derived from pre- and post-procedural pain as
defined by the use analgesics [40]. In order to quantify its use, a morphine equivalent daily dose
(MEDD) intake form was used in some studies [43]. In the case of metastatic tumors, both pain
scales and MEDD followed the standards published by the International Bone Metastases
Consensus Working Party (IBMCWP) [44]. This consensus defines a minimum follow-up of 2
weeks, 1 month, and then monthly until 6 months after delivery of FUS treatment. Longer
follow-up is considered for patients with prolonged survival. Complete response is defined as a
pain score of zero (VAS or NRS) at the treated site with no concomitant increase in analgesic
intake (stable or reducing analgesics in daily oral morphine equivalents). Partial response is
defined as any of the following: (i) pain reduction of 2 or more at the treated site on a 0–10 scale
without analgesic increase; (ii) analgesic reduction of 25% or more from baseline without an
increase in pain. Pain progression is defined as an increase in the pain score of 2 or more points
above baseline at the treated site with stable analgesic use, or an increase of 25% or more in
daily oral morphine equivalent compared to baseline with the pain score stable or 1 point above
baseline [44].
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One study [36] did not account for the interference of analgesics in pain, but similarly to
IMBCWP guidelines, considered a minimum VAS reduction of 3 points to be clinically
significant. Another study proposed their own guidelines for treatment response based on
guidance from World Health Organization standard [33].
Quality of life
Quality of life (QoL) is considered an important secondary endpoint in the majority of clinical
studies that address painful bone metastases. Pain interference with daily living is evaluated on a
0-10 scale (0 = no interference, 10 = completely interferes) with questions concerning general
activity, mood, ability to walk and work normally, relations with other people, sleep, and
enjoyment of life [4]. This assessment of functional interference related to pain was monitored
using different questionnaires. The first is described in the brief pain inventory (BPI-QoL) [42]
and the second (QLQ- BM22) was developed by the European Organization for Research and
Treatment of Cancer [45].
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3. RESULTS
The summary of all clinical studies meeting the above criteria is presented in Tables II, III and IV
for primary benign, primary malignant and metastatic bone tumors, respectively. Based on the
search criteria, 15 clinical studies were selected, which included both USgFUS and MRgFUS
treatments. The average treatment time was 2 hours, ranging from 2 minutes [35] up to 18h [19].
The procedure time was in part dependent on the type of anesthesia or conscious sedation, but
also on tumor size and blood supply. The number of treatments per site varied: the majority being
a single treatment and occasionally 2 treatments for both benign tumors and metastatic tumors.
Primary malignant tumors required up to 7 sessions [19, 33, 46]. Details on treatment planning of
image-guided FUS are outside the scope of this review, and can be found elsewhere for MRgFUS
[16] and USgFUS [33].

3.1. Primary benign bone tumors
In 2013, Napoli et al. reported on the use of MRgFUS to treat six patients with limited joint
function and reduced quality of life due to painful osteoid lesions [47]. These patients were
included in a recent 24 month follow-up, which included a total of 29 patients with osteoid
osteoma [17, 48]. Patients received therapy using MRgFUS, delivered toward the nidus,
identified on MRI and/or CT. The treatment was well tolerated and no adverse events were
recorded with follow-up up to 24 months. Complete clinical response occurred in 27/29 patients
as defined by absence of pain and no intake of analgesics. VAS decreased dramatically in these
patients: from 7.9 at baseline to 0.7 on average at the last follow-up (12-24 months). Two patients
reported pain recurrence with average VAS=5 requiring subsequent CT-guided radiofrequency
ablation. Imaging evaluation with CE-MRI demonstrated edema and hyperemia decrease in every
lesion associated with complete response. At CT, bone remodeling was evident in all complete
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responders, and nidus fading was demonstrated in 15/27 patients. No complications were
observed.
Arrigoni and his colleagues [49] treated 12 painful epiphyseal benign bone lesions with
MRgFUS. After the treatment, 11 patients had pain regression with a mean VAS that decreased
from 7.8 to 2.1 on average, 12 months after treatment. A patient with periosteal chondroma did
not experience improvement. With 12 month follow-up, 8 patients did not show any signs of
edema on MRI. No substantial changes were found in CT images, but in 3 cases they observed a
recovery of the normal morphological structure of bone. No major complications were observed.
From March 2013 to May 2014, 7 consecutive patients with superficial osteoid osteomas of the
lower limb were treated with MRgFUS [50]. The mean VAS at the baseline was 7.5. In all
patients VAS dropped to 0 after 1 month. In 6 patients VAS remained at 0 during the follow-up,
while in 1 patient VAS dropped from 9 to 0 after 1 month, but rose to 2 after 3 months (6-month
control available, no recurrence documented). No adverse events were observed.

3.2. Primary malignant bone tumors
The first FUS treatment performed in bone was in China, in a tibial osteosarcoma on December
1997. Through October 2001, a total of 1038 patients with solid tumors had undergone
extracorporeal USgFUS ablation in 10 Chinese hospitals. 153 were bone tumors and 44 were
reported [34]. Among them, FUS was performed as a limb-salvage treatment in combination with
neoadjuvant chemotherapy in 34 patients (Enneking’s stage IIb). The remaining ten patients were
stage IIIb (nine patients with lung metastasis) and were treated with FUS alone with palliative
intent. Histopathological examination demonstrated clear evidence of tumor destruction and
regrowth of normal bone in the treated region. Follow-up diagnostic imaging revealed that there
was no, or reduced, blood supply, and no uptake of radioisotope in the FUS treated tumor, both
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indicating a positive therapeutic response and absence of viable tumor (no response rate
available). Furthermore, both CE-MRI and bone scans indicated complete coagulation necrosis of
the treated tumors. At 6-12 month follow-up, imaging showed obvious regression of the lesion
and the region of induced coagulation necrosis. Most frequently, the nonenhancing treated
volume decreased by less than 20-50% in volume. The follow-up range was 10-40 months, and
the overall survival rate was 85% (38/44). One patient with stage IIb disease, and five patients
with stage IIIb disease died as a result of distant metastases. Five patients underwent amputation
due to local recurrence. Few major complications were observed during follow-up period (8%),
including pathological fractures in three patients, peripheral nerve damage in two, restricted joint
movement in one, and epiphyseal separation in another one.
Li et al. evaluated 13 patients diagnosed with primary bone tumors, primarily osteosarcomas,
treated with USgFUS [33]. At a 6 month follow-up, PET/CT and SPECT showed no abnormal
radioactivity concentrations in the tumor areas; the areas became cold lesions of the size and
shape of the original bone tumor. The pain was quantified in a scale ranging from 0-3, and
decreased, on average, from 1.85 at baseline to 0.08 at the follow-up. The response rate for
patients with primary bone tumors was significant: 6 (46%) patients had CR, 5 (38%) had PR, 1
(8%) had moderate response, and 1 (8%) had PD. The overall response rate was 85%. The 1-, 2-,
3-, and 5-year overall survival rates were 100%, 85%, 69%, and 39%, respectively. No
abnormalities in electrocardiogram, liver, and kidney functions and blood electrolytes were
detected. After two months, alkaline phosphatase and lactic acid dehydrogenase returned to
normal levels [33].
In 2010, Chen et al. reported long-term follow-up results of a non-randomized clinical trial [19].
The group used USgFUS for the treatment of 80 primary malignant tumors, including 60 stage
IIb and 20 stage IIIb (Enneking staging) patients. FUS combined with chemotherapy was
15

performed in 62 patients with osteosarcoma, 1 with periosteal osteosarcoma and 3 with Ewing's
sarcoma. The remaining 14 patients with chondrosarcoma, malignant giant cell tumor of bone,
sarcoma of the periosteum or with unknown histology received FUS alone. Follow-up images
demonstrated complete ablation of the tumors in 69 patients and greater than 50% tumor ablation
in the remaining 11 patients. The overall 5-year survival rate was 51%, with 64% and 16% for
patients with stage IIb and III disease, respectively. Among the patients with stage IIb disease,
long-term survival rates were substantially improved in 30 patients that received combined
treatment with FUS and chemotherapy (86% 5-year survival rate), in comparison with the
survival rates for 24 patients that did not finish chemotherapy and six patients who underwent
partial ablation only (36% 5-year survival rate). Only five of the 69 patients who underwent
complete ablation had local cancer recurrence during the follow-up period (5-87 months). All
patients experienced mild pain and among other adverse events, 28% were major complications
[39], where 11 of these patients required surgery and 8 presented severe peripheral nerve damage.
In these cases, the distance between the damaged nerves and the tumor margin was less than 10
mm, suggesting that 10 mm is a reasonable safety margin to avoid nerve damage in FUS
treatments.
The most recent USgFUS malignant bone tumor treatment series reported in literature was in
2013, by Wang et al. [46]. Eleven patients with primary malignant tumors of the bony pelvis
received USgFUS for both palliative (7 patients) and curative purposes (4 patients). The efficacy
of FUS ablation was only assessed by CE-MRI. With median follow-up of 22 months (11-154
months), seven patients that received palliative ablation died of metastatic disease. Enlargement
of residual tumor was observed in all patients receiving palliative FUS ablations 6-24 months
after study entry. The remaining four patients that received ablation with curative intent were
alive at the time of the publication. Local recurrence was observed in one patient receiving
16

curative FUS ablation, which was retreated by additional FUS ablation; no local recurrence was
observed thereafter. Significant coagulative necrosis was obtained in all patients, with an average
volume ablation ratio of 87% (range 65-100%). Complete tumor necrosis was achieved in all
patients receiving curative FUS ablation. No major complications were encountered.

3.3. Metastatic bone tumors
Liberman et al. in 2009 published the first multicenter clinical study on the use of FUS for pain
palliation of bone metastases [21]. This report includes previous pioneer work from [18] and
[20], comprising 31 patients and 32 bone lesions. 3-month follow-up was available for 25 out of
31 patients. Eighteen patients (72%) had a significant reduction in pain (>2 points) and 9 (36%)
reported a VAS score of 0. The average VAS score decreased from 5.9 prior to treatment to 1.8 at
the 3-month follow-up; with 52% of patients reporting substantial pain relief within 3 days.
Twenty-four percent had no response and one patient (4%) experienced worsened pain levels. A
reduction in opioid usage was reported in 67% of patients with recorded medication data. No
major complications were reported.
Li et al. also reported on 12 patients with bone metastases treated with USgFUS [33]. 96% of the
patients suffered pain before the procedure. Pain decreased from 1.75 at baseline to 0.17 on a 0-3
scale at the last follow-up (4-6 months). Response rates were classified by MRI or PET/CT and
not pathologically: 5 (42%) complete response, 4 (33%) partial response, 1 (8%) had progressive
disease, with the overall response rate as 75%. The 1-, 2-, 3-, and 5-year overall survival rates
were 83%, 17%, 0%, and 0%, respectively.
Napoli et al., in 2013, reported a prospective, single-arm research study with 18 patients treated
with MRgFUS for painful bone metastases [37]. The pain severity score changed significantly
from a baseline average of 7.1 to 1.1 at 3-month follow-up. A score of 0 for pain severity,
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without medication intake, was reported by 13/18 patients (72%) at final follow-up, consistent
with a complete response to treatment. CT examinations demonstrated increased bone density
with restoration of cortical borders in 5/18 patients (28%). According to the MDA criteria [41], a
complete response to treatment was observed in 2/18 patients (11%), a partial response in 4/18
patients (22%), stable disease in 10/18 patients (56 %) and progressive disease in 2/18 patients
(11%). No treatment-related adverse events were recorded during the study.
The results of the first phase III clinical trial on bone tumors were published in 2014 by Hurwitz
et al. [43]. 147 patients with metastatic bone pain, typically refractory to radiation and other pain
interventions, were randomized to MRgFUS treatment or placebo treatment. Patients randomized
to placebo underwent the same procedure as those receiving MRgFUS treatment but without
energy deposition. The pain response rates three months after treatment were 64% in the
MRgFUS treated arm versus 20% in the placebo arm. Complete pain relief was observed in 23%
of treated patients, compared to 6% of patients who received placebo treatment. Approximately
two-thirds of responders experienced significant pain relief - as defined as a decrease in worst
NRS score by 2 points or more - within three days of treatment, establishing the ability of
MRgFUS to induce fast pain response. This response was accompanied by a similarly rapid
improvement in patient function scores. The most common complication was pain during
MRgFUS treatment (32%) and major complications (third degree skin burn, fracture) occurred in
4% of treated patients. However, one fracture was outside the treated area, and the skin burn was
due to a violation on the inclusion criteria protocol. Furthermore, the majority of adverse events
(60%) were transient and resolved on the treatment day and 51 patients (46%) had no adverse
events.
In 2014, Huisman and colleagues reported the first experience with volumetric MRgFUS for
palliative treatment of painful bone metastases [51]. In this technique, the focal spot is iteratively
18

switched to well-separated positions around a circular trajectory and sonications are repeated
continuously till ablative temperatures are achieved throughout increasing diameter concentric
circles. The resulting volumetric temperature rise contrasts with more traditional raster scan
iterative sonications where each overlapping focal ablation is followed by a cooling period. The
goal is improvement in ablation zone homogeneity, energy efficiency, and overall treatment time
[52]. Pain inventories were implemented at 3 days and 1 month after treatment for 11 patients. At
3 days after volumetric MR-FUS ablation, NRS pain scores decreased significantly from 8 to 6
on average, and a response was observed in a 6/11 patients (55%). At 1-month follow-up, 9
evaluable patients had NRS pain scores decreased significantly compared to baseline from 8 to 4
on average and 6/9 patients obtained pain response. The overall response rate was 67% with 0%
pain recurrence at 1-month follow-up. No treatment-related major complications were observed.
The phase III trial as reported by Hurwitz et al. was subject recently to a retrospective analysis of
the safety of combination MRgFUS with active systemic chemotherapy [53]. Chemotherapy data
were available for 104 patients. Patients were followed for 3 months. Ninety patients were treated
without chemotherapy, and fourteen were treated with chemotherapy. There was no significant
difference between the response rates of the chemotherapy group (71%) and the nonchemotherapy group (68%). The overall adverse event rates were 57% for chemotherapy patients
and 45% for non-chemotherapy patients. Sonication pain was not significantly different between
the groups, with 50% pain in the chemotherapy group and 28% pain in the non-chemotherapy
group. Remaining adverse event rates were not significantly different (p=0.17).
A prospective, single arm, multicenter study was performed to evaluate the efficacy of MRgFUS
for pain palliation of bone metastasis in patients who had exhausted radiotherapy or refused other
therapeutic options [54]. 72 patients with painful bone metastases were enrolled. 34/72 patients
(47%) reported complete response to treatment and discontinued medications. 29/72 patients
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(40%) experienced a pain score reduction >2 points, consistent with partial response. The
remaining 9 patients (13%) had recurrence after treatment. Significant differences between
baseline (6) and follow-up (2) average VAS values and medication intake were observed.
Similarly, a significant difference was found for QLQ-BM22 between baseline and follow-up
(p<0.05). No treatment-related adverse events were recorded.
Finally, Bazzocchi et al. evaluated the clinical outcome of 39 patients (57 lesions) with painful
bone metastases that were treated with MRgFUS [55]. Nine patients had a single bone metastasis,
while 5 of them showed no other distant metastasis. The follow-up schedule included 1-, 3-, 6-,
and 12-month evaluations. Forty-five lesions were evaluated after 1 month, while 31 lesions
reached the 3-month (54%), 17 the 6-month (30%) and 8 the 12-month (14%) follow-up point.
Four patients died during follow-up and 3 lesions required retreatment. On a lesion-based
approach, average VAS score at baseline was 5.2 decreasing to 2.5 at 1 month, and to 2.0, 2.1,
and 1.2 after 3, 6 and 12 months respectively. In 14/45 lesions (31%) the VAS dropped to 0 one
month after the treatment; VAS persisted at the 0 level in 8 patients up to 3 months, in 5 patients
up to 6 months, and in 3 patients up to 12 months. The major determinant of MRgFUS success
was lesion size, with smaller lesions corresponding to higher efficacy in terms of pain relief possibly due to more efficient tumor debulking. Two treatment-related adverse events were
reported: a single case of small skin burn, and one case of prostate inflammation in a patient
treated to the ichiopubic ramus.
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4. DISCUSSION
The use of image-guided FUS has increased significantly in the past decade. The ability to
deliver treatments accurately and non-invasively is a great advantage of image-guided FUS for
the treatment of bone tumors. Contrary to ionizing radiation, image-guided FUS treatments can
be repeated without the risk of cumulative dose effects in normal tissues outside the target. Also,
thermal dose may be confined precisely to a small treatment volume (typically 0.2-20 mm3)
without the need for invasive implants like microwave, radiofrequency, laser, and cryoablation
techniques (Table I). Furthermore, the extent of treatment is readily controlled in three
dimensions, which provides safe non-invasive conformal treatments that spare healthy tissue.
Efficacy
Standardization of validated assessment instruments facilitates comparisons of clinical studies. In
this respect, the IBMCWP guidelines are seeing increasing use for evaluation of palliative
treatments, which allows direct comparison of treatment outcomes. However, not all studies
followed the same criteria, making comparison more challenging. For instance, Geiger et al.
(2014) used a 10-point pain scale (1-10), Li et al. (2010) a 4-point pain scale (0-3), while the
remaining studies used the IBMCWP 11-point pain scale (0-10). In the case of curative
treatments, there are greater challenges comparing different studies since the number of patients
varied widely and different endpoints were reported such as imaging, biochemical analyses, and
survival rates. Taking into account overall response inclusive of complete and partial responses
as a baseline for comparisons, the responders group varied within 92-100%, 85-87% and 64-87%
for primary benign, primary malignant, and metastatic tumors, respectively. In treatments with a
curative aim the recurrence rate was 0-14%, and in palliative treatments the pain progression was
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0-13%. These results demonstrate the efficacy of FUS for both palliative and curative purposes in
the treatment of bone tumors.
Safety
Similar to response, challenges exist in assessing safety across studies. Different studies used
different classifications for adverse events. Therefore, for summary purposes we defined adverse
events according to minor and major complications [39]. Overall, studies of benign tumors
reported 0-66% minor and 0% major complications. Patients treated for primary malignant
tumors presented higher complication ranges: 45-100% minor and 0-28% major complications.
Finally, patients with metastatic tumors presented complication ranges similar to the first group:
0-51% minor and 0-4% major complications. The most frequently observed complications were
mild skin burn - usually resolving by one-two weeks after FUS - and sonication pain during
treatment. Several authors inferred that skin burns were most likely due to lack of operator
experience or not following established protocols. The lack of adverse events in some studies [17,
37, 47, 48, 50, 54, 55] may relate to the limited number of patients. In clinical studies with large
number of patients, an USgFUS study [19] reported a major complication rate of 28% (22/80) for
patients with primary malignant tumors. This was in large part due to lack of guidelines to protect
normal structures, e.g. there were 8 serious nerve injuries as treatment guidelines did not limit
proximity to nerves. Other primary malignant studies implemented a 1 cm tumor margin limit
and major complications were limited to 8%. On the other hand, MRgFUS produced only 4%
(4/112) major complications in patients with bone metastases. Overall, the data provides strong
evidence that FUS is safe for treatment of bone metastases and primary benign lesions, while
other applications are still under investigation.
Sonication pain was the most common complaint during conscious sedation or epidural
anesthesia. General anesthesia provides an advantage in terms of alleviation of sonication pain.
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Also, it ensures intraoperative immobilization which facilitates ultrasound targeting. However,
the use of anesthesia does not allow patient feedback on pain and that could risk serious normal
tissue damage [33]. As such, the optimization of patient anesthesia relative to complication rates
requires further investigation, especially in treatment sites near critical tissue structures.
US vs MR guidance
Both MR and US imaging have been used to guide FUS in the treatment of bone tumors. Both
imaging methods have advantages and disadvantages. Ultrasound imaging devices are less
expensive, widely available, capable of real-time visualization, and clinically proven in the
treatment of organs such as liver and kidney which move with respiration. The main disadvantage
of US is poorer imaging resolution than MRI, especially in areas that have air or bone.
Furthermore, nerves cannot be visualized by ultrasound imaging, and are thus difficult to avoid in
the beam path. This is especially relevant because nerves are sensitive to ultrasonic energy and
tumors are often located adjacent to nerves.
MRI can provide three-dimensional imaging with better resolution, which allows accurate tumor
delineation. Also, MR allows continuous monitoring of temperature distribution within the
treatment zone and thus measures both normal and target tissue temperature rise during FUS
exposure. Since rapid protein denaturation occurs above 60°C, sonications lead quickly to
coagulative necrosis which is readily imaged by MR. The combination of these features - high
resolution pre-treatment target visualization, MR thermometry during treatment to spare adjacent
healthy tissue, and immediate post-treatment verification of effective treatment zone - makes MR
guidance a highly attractive component of focused ultrasound therapy.
Despite the advantages, MR adds high cost, long treatment time, and problems in tracking
moving targets, e.g. ribs, which may limit application of MRgFUS. MR temperature imaging is
limited primarily to the soft tissues adjacent to bone since the PRFS method does not work well
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to calculate temperature rise in low water content bone cortex, bone marrow and fat tissue.
However, the received thermal feedback is sufficient to allow control of actual sonication
location and minimization of damage to non-target tissues [21]. This approach affords the
treating physician a ‘closed loop’ monitoring of the treatment in real time, resulting in a high
level of safety and efficacy [18]. Also, the reduced major complications associated with
MRgFUS will reduce the overall hospitalization time. Thus, although more expensive initially,
MRgFUS can decrease overall patient care cost [17]. In any case, direct comparison of safety and
efficacy between MRgFUS and USgFUS is not possible since USgFUS was used mainly for
primary malignant tumors whereas MRgFUS was used for benign and metastatic tumors. The
only study on bone metastases was a subset from Li et al. [33] which did not show significant
differences in terms of adverse events and response rates.
Future directions
The success of FUS ablation in the clinical studies summarized above demonstrates the promise
of image-guided FUS and suggests further investigation is needed in larger numbers of patients
with primary and secondary bone tumors. Three clinical trials are currently recruiting to evaluate
MRgFUS in pain palliation of bone metastases: NCT01833806, NCT01964677 and
NCT01586273. Other aspects could be addressed such as the correlation between site of
metastases or primary tumor type and treatment outcome, local effect on the progression of bone
metastases, long-term durability of pain palliation, and long-term durability of bone strength.
Furthermore, the low procedure morbidity and short treatment time suggests that MRgFUS may
also be a viable treatment option for patients with multifocal bone metastases. As pointed out by
Gianfelice and his colleagues [20], treatment for multifocal disease can be repeated with no
obvious increase in treatment morbidity. Expansion of indications for FUS inclusive of spinal
treatments whether invasive [56] or non-invasive will significantly expand the number of patients
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that may benefit from this treatment modality. Finally, additional randomized studies for
malignant

lesions

using

multimodality

approaches

including

FUS

are

warranted.
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5. CONCLUSIONS
Focused ultrasound is a treatment modality with both emerging and established roles in treatment
of bone tumors. While most research has focused on MR guidance, both MR and US guidance
have been studied with promising results. As phase III trials are yet to be completed for treatment
of primary tumors, further study is warranted, particularly for primary malignant tumors, before
FUS can be considered standard of care across all clinical applications related to bone lesions.
Comprehensive review of studies to date, however, indicates that use of FUS to treat primary
benign tumors, primary malignant tumors, and metastatic tumors is both safe and effective.
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Table I. Thermal ablation techniques for bone cancer treatement.
Bone Tumor
Primary malignant
osteosarcoma
Other primary
malignant tumors
Primary benign
osteoid osteoma
Other primary
benign tumors
Bone metastasis

USgFUS

MRgFUS

RFA

MWA

Laser ablation

Cryoablation

[19, 33, 34, 46]

-

-

[57]

[58]

-

[19, 33, 34, 46]

[5, 19, 33, 46, 49]

[59]

[60]

-

[61]

-

[17, 48, 50]

[62, 63]

[64]

[65]

[66]

-

[67]

[68-71]

[72]

-

[73]

[33]

[16, 18, 20, 21, 36, 43, 53-55]

[74, 75]

[76]

-

[77]

Abbreviations for Tables II-IV: MR, magnetic resonance; US, ultrasound; IBMCWP, International Bone Metastasis Consensus
Working Party; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale; NRS, Numeric Rating Scale; QoL, Quality of Life; BPI,
Brief Pain Inventory; MDA criteria, MD Anderson criteria; OR, overall response; CR, complete response; PR, partial response; PP,
pain progression; NR, no response; RR, recurrence; AE, adverse event; SR, survival rate.
Table II. Clinical studies of image-guided FUS for primary benign bone tumors.
Study
Patients
Primary Tumor Endpoints
Device + Follow-up
Guidance

Outcome
assessment

Outcome (a= average, m =
months, y = years)

Napoli
2014 [48]
Geiger
2014 [17]
Arrigoni
2014 [49]
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Osteoid osteoma

Palliation,
Efficacy,
Safety,

ExAblate
+ MR

1, 6, 12, 24
months

IBMCWP
guidelines,
Imaging

93% CR, 7% PP (12-24m)
aVAS = 7.9 → 0.7 (12-24m)
0% AE (24m)

12

Palliation,
Efficacy

ExAblate
+ MR

6, 12
months

VAS,
Imaging

Bazzocchi
2014 [50]

7

Fibro-osteitis (7)
Periosteal
chondroma (2)
Others (3)
Osteoid osteoma

Palliation,
Safety,
QoL

ExAblate
+ MR

1,3, 6, 12
months

VAS, QoL

92% OR, 8% NR, 0% PP (12m)
aVAS = 7.8 → 2.1 (12m)
AE: 66% minor, 0% major
(12m)
86% CR, 14% PR, 0% PP (112m)
aVAS = 7.5 → 0.3 (1-12m)
0% AE (1-12m)
27

Table III. Clinical studies of image-guided FUS for primary malignant bone tumors.
Study
Patients
Primary Tumor
Endpoints
Device +
Follow-up Outcome
Guidance
assessment
Wu 2004
[34]

44

Malignant (44)
Stage IIb (34)
Stage IIIb (10)

Li 2010
[33]

13

Osteosarcoma (12)
Fibrous Histiocytoma
(1)

Outcome (a= average, m =
months, y = years)

Palliation
(Stage IIIb),
Limb
conservation
(Stage IIb),
Safety,
Survival
Palliation,
Safety,
Survival

JC Haifu +
US

10-39
months

Kaplan-Meier
method,
Biochemical
analysis,
Amputation
rate, AE

11% RR (lead to amputations)
AE: 45% minor, 8% major (1-12m)
SR: 85% (10-39m)

JC Haifu +
US

1,4,6
weeks, 4
,6 months

VRS, AE,
Imaging,
Biochemical
analysis

Kaplan-Meier
method,
Imaging,
Blood
analysis, AE
Imaging

85% OR, 8% RR (4-6m)
46% CR, 39% PR (4-6m)
aVRS 1.85 →0.08 (4-6m)
AE: 68% minor, 0% major (4-6m)
SR: 100% (1y), 85% (2y), 69%
(3y), 39% (5y)
86% CR, 14% NR (2-8w)
6% RR (2y), 12% RR (5y)
AE: 100% minor, 28% major (5y)
SR: 90% (1y), 72% (2y), 61% (3y),
51% (4y) and 51% (5y)
87% OR (1d), 0% RR and 0% PP at
the time of publication
AE: 100% minor, 0% major

Chen
80
2010 [19]

Osteosarcoma (63)
Other sarcomas
(13)
Others (4)

Efficacy,
Safety,
Survival

JC Haifu
+ US

1,2,3,4,5
years

Wang
11
2013 [46]

Osteosarcoma (4)
Ewing’s sarcoma (2)
Chondrosarcoma (2)
Others (3)

Palliation,
Local tumor
control

JC Haifu
+ US

1,3, 6,
every 6
months
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Table IV. Clinical studies of image-guided FUS for painful bone metastases.
Study
Patients Primary
Endpoints
Device +
Follow-up
(lesions) Tumor
Guidance

Outcome
assessment

Liberman
2009 [21]

31 (32)

IBMCWP
guidelines

Li 2010
[33]

12

Napoli
2013 [37]

18

Hurwitz
2014 [43]

112

Huisman
2014 [51]

11 (12)

Meyer 2014
[53]

104

Zaccagna
2014 [54]

72 (87)

Bazzocchi
2014 [55]

39 (57)

Breast (11)
Kidneys (6)
Prostate (5)
Others (9)
Liver (5)
Lung (4)
Kidney (1)
Others (2)

Palliation,
Safety

ExAblate
+ MR

3 days,
2 weeks,
1, 3, 6
months
1, 4, 6
weeks,
4, 6 months

Palliation,
Safety,
Survival

JC Haifu
+ US

Lung (5)
Breast (4)
Kidney (3)
Others (6)
Breast (34)
Lung (17)
Prostate (15)
Others (44)
Kidney (3)
Colorectal (3)
Breast (2)
Others (3)
Subset from
Hurwitz et
al, 2014
Not provided

Palliation,
Local tumor
control

ExAblate
+ MR

1,3, 6
months

Palliation,
Safety, QoL

ExAblate
+ MR

2, 5, 7, 14,
30, 60, 180
days

Safety,
Efficacy,
Technical
feasibility
Efficacy,
Safety

Sonnallev
e+MR

3 days,
1 month

ExAblate
+ MR

3 months

Palliation,
QoL

ExAblate
+ MR

1, 3 6
months

Breast (15)
Kidney (5)
Others (18)

Palliation,
Safety, QoL

ExAblate
+ MR

1, 3, 6, 12
months

Outcome (a= average VAS, m = months,
y = years)

72% OR, 4% PP (3m)
36% CR, 36% PR, 24% NR (3m)
aVAS = 5.9 → 1.8 (3m)
AE: 0% (3m)
VRS,
75% OR, 8% PP (4-6m)
Imaging,
42% CR, 33% PR (4-6m)
Biochemica aVRS = 1.75 → 0.17 (4-6m)
l analysis
SR: 83% (1y), 17% (2y), 0% (3y)
AE: 68% minor, 0% major (4-6m)
IBMCWP
89% OR (3m)
guidelines, 72% CR, 17% PR, 11% PP (3m)
BPI, MDA aVAS = 7.1 → 1.0 (3m)
criteria
AE: 0% (3m)
IBMCWP
64% OR, 23% CR (3m)
guidelines, aNRS reduced 3.6 points (3m)
BPI
AE: 51% minor, 4% major (3m)
60% of AEs solved in 1d
IBMCWP
67% OR (1m)
guidelines
11% CR, 56% PR, 0% PP (1m)
aVAS = 8 → 4 (1m)
AE: 18% minor, 0% major (1m)
IBMCWP
Responders, AE, Sonication pain:
guidelines, 68%, 45%, 28% (FUS)
BPI
71%, 57%, 50% (FUS+chemo)
IBMCWP
47% CR, 40% PR, 13% PP (6m)
guidelines, aVAS = 6 → 2 (6m)
QLQ-BM22 AE: 0% (6m)
VAS
aVAS = 5.2 → 1.2 (12m)
AE
VAS = 0 (1m) in 31% patients
AE: 5% minor, 0% major (12m)
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